Phospho-NTRK1 (Tyr791) Antibody

What is NTRK1 and why is phosphorylation at Tyr791 specifically important in research?

NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), also known as TrkA, functions as a high-affinity receptor for Nerve Growth Factor (NGF), which is its primary ligand. It can also bind and be activated by NTF3/neurotrophin-3, though with different functional outcomes . NTRK1 plays critical roles in the development and maturation of both central and peripheral nervous systems by regulating proliferation, differentiation, and survival of sympathetic and nervous neurons .

Phosphorylation at Tyr791 occurs following NGF binding, which triggers receptor homodimerization and autophosphorylation . This specific phosphorylation site is crucial because:

• It serves as an activation marker for NTRK1 signaling

• It contributes to downstream pathway activation

• It is involved in the regulation of neuronal survival and differentiation

• Its detection allows researchers to specifically monitor the activated form of NTRK1

Importantly, mutations in NTRK1 have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation, and certain cancers .

How do phospho-specific NTRK1 antibodies differ from total NTRK1 antibodies in experimental applications?

Phospho-specific antibodies allow researchers to distinguish between inactive and activated forms of NTRK1, providing critical information about receptor activation status that total NTRK1 antibodies cannot reveal .

What are the recommended protocols for validating Phospho-NTRK1 (Tyr791) Antibody specificity?

Validation of phospho-specific antibodies is crucial for reliable experimental results. A comprehensive validation approach should include:

• Knockout/knockdown controls: Use NTRK1 knockout tissues or cells as negative controls to confirm specificity .

• Phosphatase treatment: Split your samples and treat half with lambda phosphatase to remove phosphorylation—the signal should disappear in phosphatase-treated samples .

• Stimulation/inhibition experiments: Compare samples with:

  • Unstimulated (basal) cells

  • NGF-stimulated cells (should increase phospho-signal)

  • Cells treated with NTRK1 inhibitors before stimulation (should block phospho-signal)

• Multiple detection methods: Validate across different techniques:

  • Western blotting (should show a single band at ~140 kDa)

  • Immunohistochemistry (with peptide blocking controls)

  • Immunofluorescence (with peptide competition)

• Cross-reactivity assessment: Test the antibody against other phosphorylated TRK family members (NTRK2/TrkB, NTRK3/TrkC) to ensure specificity .

Recent research has highlighted significant variability among commercial NTRK1 antibodies. A study evaluating seven commercial antibodies found that only one showed true specificity when tested against knockout samples . This emphasizes the critical importance of thorough validation.

What are the optimal sample preparation procedures for detecting phosphorylated NTRK1?

Phosphorylation states are notoriously labile, requiring specific sample handling to preserve them:

• Cell/Tissue Lysis:

  • Use ice-cold lysis buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Include protease inhibitors to prevent protein degradation

  • Perform lysis quickly and maintain samples at 4°C throughout processing

• Sample Preservation:

  • For tissues: Flash-freeze immediately after collection

  • For cell culture: Stimulate directly in the plate and lyse without detachment when possible

  • Consider using crosslinking fixatives like paraformaldehyde for phospho-specific IHC/IF applications

• Recommended Buffer Composition:

  • 50 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% NP-40 or 1% Triton X-100

  • 5 mM EDTA

  • 1 mM Na₃VO₄ (phosphatase inhibitor)

  • 10 mM NaF (phosphatase inhibitor)

  • 1 mM PMSF (protease inhibitor)

  • Commercial protease inhibitor cocktail

• Storage Conditions:

  • Maintain at -20°C for short-term (up to 2 weeks)

  • Store at -80°C in small aliquots for long-term storage

  • Avoid repeated freeze-thaw cycles that can degrade phosphorylation

How should dilution optimization be performed for different applications?

Based on the search results, here are the recommended dilution ranges and optimization strategies for different applications:

Optimization Protocol:

• Perform an initial titration experiment using a sample known to express phosphorylated NTRK1

• Include positive controls (NGF-stimulated samples) and negative controls (phosphatase-treated or inhibitor-treated samples)

• For each application, determine the highest dilution that maintains a clear specific signal while minimizing background

• Validate the optimal dilution using different sample types relevant to your research

How can Phospho-NTRK1 (Tyr791) Antibody be used to investigate NTRK1-targeted cancer therapies?

NTRK1 gene rearrangements have been identified in several cancer types, including glioblastoma, non-small cell lung cancer, and colorectal cancer . These rearrangements lead to constitutive activation of NTRK1 with high transforming ability.

Research Applications:

• Monitoring Treatment Response:

  • Evaluate changes in Tyr791 phosphorylation following treatment with NTRK inhibitors like entrectinib and larotrectinib (LOXO-101)

  • Correlate phosphorylation status with clinical outcomes and tumor characteristics

  • Use as a pharmacodynamic biomarker in clinical trials

• Resistance Mechanism Studies:

  • Detect acquired resistance mutations (G595R, G667C) that affect kinase domain function

  • Identify bypass pathway activation (e.g., IGF1R signaling) when phospho-NTRK1 levels decrease but downstream signaling remains active

  • Screen potential combination therapies (e.g., cabozantinib with IGF1R inhibitors) that overcome resistance

• Experimental Approach:

  • Compare phospho-NTRK1 levels in parental and resistant cell lines

  • Use with phospho-specific antibodies targeting downstream effectors (ERK, AKT)

  • Employ in patient-derived xenograft models to validate clinical observations

  • Combine with genetic sequencing to correlate mutation status with phosphorylation patterns

A comprehensive resistance study by identifying novel NTRK-TKI resistance mutations found that ponatinib and nintedanib effectively inhibited certain resistant mutants (G667C) but not others (G595R), demonstrating the importance of monitoring phosphorylation status when developing therapeutic strategies .

What are the key considerations when analyzing phosphorylated NTRK1 in neurological research?

NTRK1 plays critical roles in neuronal development, particularly in the cholinergic nervous system. Phospho-NTRK1 antibodies can provide valuable insights into neurological mechanisms and pathologies:

• Expression Pattern Analysis:

  • NTRK1 is expressed in specific brain regions, including the striatum, basal forebrain, and paraventricular thalamic nucleus (PVT)

  • The anterior PVT shows high expression, while the posterior PVT exhibits lower expression

  • Use phospho-specific antibodies to map activation patterns within these regions

• Methodological Considerations:

  • Brain tissue requires special handling to preserve phosphorylation

  • Perfusion fixation protocols must be optimized to maintain epitope accessibility

  • Consider using phosphatase inhibitors in perfusion buffer

  • Background autofluorescence may interfere with detection in brain tissue

• Disease Model Applications:

  • Study phosphorylation changes in models of congenital insensitivity to pain with anhidrosis (CIPA)

  • Investigate neurodevelopmental disorders associated with NTRK1 mutations

  • Examine neurodegeneration models where NGF signaling may be compromised

Recent research has identified a novel NTRK1 splice site variant (c.850 + 5G>A) causing congenital insensitivity to pain with anhidrosis. This variant results in abnormal protein production and disrupts the immunoglobulin-like domain crucial for NGF binding, highlighting the importance of proper NTRK1 function and phosphorylation in pain sensation and autonomic regulation .

What technical limitations and troubleshooting approaches should researchers be aware of when working with Phospho-NTRK1 (Tyr791) antibodies?

Common Technical Challenges:

• Antibody Specificity Issues:

  • Significant quality differences exist between commercial antibodies

  • Batch-to-batch variability can affect performance

  • Cross-reactivity with other phosphorylated proteins may occur

• Signal Detection Problems:

  • Rapid dephosphorylation during sample processing

  • Low expression levels in certain tissues

  • Epitope masking due to protein-protein interactions

  • Fixation-induced epitope alterations

Troubleshooting Approaches:

A comprehensive study evaluating seven commercial NTRK1 antibodies reported that only one demonstrated true specificity in western blots when tested against knockout samples. This underscores the importance of thorough validation, especially when using phospho-specific antibodies for quantitative analyses .

How does phosphorylation at Tyr791 integrate with other NTRK1 phosphorylation sites in signaling cascades?

NTRK1 undergoes autophosphorylation at multiple tyrosine residues upon NGF binding, with each site contributing differently to downstream signaling:

• Tyr791 in the Signaling Network:

  • Located in the kinase domain

  • Contributes to kinase activation and stability

  • Influences substrate recognition and binding

  • May modulate interactions with adaptor proteins

• Comparison with Other Key Phosphorylation Sites:

• Signaling Integration:

  • Phosphorylation at Tyr791 occurs after phosphorylation at Tyr674/675 in the activation loop

  • Together with other phosphorylation events, Tyr791 contributes to full activation of NTRK1

  • Sequential phosphorylation creates binding sites for different effector proteins

Research has shown that NTRK1 phosphorylation initiates signaling cascades that activate important pathways including MAPK and PI3K. These activation events lead to various cellular responses such as proliferation, differentiation, and survival of neurons . Understanding the specific contribution of Tyr791 phosphorylation within this network provides critical insights into NTRK1 function in both normal development and disease states.

What are the latest findings regarding NTRK1 phosphorylation in cancer biomarker development?

Recent research has established NTRK1 gene rearrangements as oncogenic drivers across multiple cancer types. The phosphorylation status of NTRK1 at Tyr791 is emerging as a potential biomarker with several key applications:

• Diagnostic Applications:

  • Distinguishing between inactive and constitutively active NTRK1 fusion proteins

  • Identifying patients likely to respond to NTRK inhibitors

  • Complementing genomic testing to confirm functional activation

• Treatment Monitoring:

  • Early assessment of treatment response before morphological changes

  • Detection of emerging resistance mechanisms

  • Guidance for switching therapies when phosphorylation patterns change

• Resistance Mechanism Identification:

  • Persistent Tyr791 phosphorylation despite treatment suggests mutation in drug binding site

  • Loss of Tyr791 phosphorylation with continued downstream signaling indicates bypass pathway activation

  • Altered phosphorylation patterns may reveal novel resistance mechanisms

Studies have identified multiple novel NTRK-TKI resistance mutations in the NTRK1 kinase domain (including G595R) and IGF1R bypass pathway-mediated resistance. These findings have led to the development of alternative inhibitors like cabozantinib that may overcome resistance when combined with IGF1R inhibitors .

How can dual immunostaining with Phospho-NTRK1 (Tyr791) and other markers advance neurodevelopmental research?

Dual immunostaining approaches combining phospho-NTRK1 detection with other neuronal markers provide powerful tools for neurodevelopmental research:

• Recommended Marker Combinations:

• Protocol Optimization:

  • Sequential rather than simultaneous staining may preserve phospho-epitopes

  • Tyramide signal amplification can enhance detection of low-abundance phosphorylation

  • Consider automated multiplexing platforms for consistent results

  • Always include single-stained controls to verify antibody specificity

• Application Examples:

  • Mapping developmental activation patterns in animal models

  • Studying activity-dependent phosphorylation in neuronal cultures

  • Investigating aberrant signaling in neurodevelopmental disorders

Recent studies have shown NTRK1 is expressed in specific brain regions including the striatum, basal forebrain, and paraventricular thalamic nucleus, with differential expression patterns between anterior and posterior regions. Co-staining with appropriate neuronal markers can help elucidate the functional significance of these expression patterns and associated phosphorylation events .

What considerations are important when using Phospho-NTRK1 (Tyr791) antibodies in high-throughput screening applications?

High-throughput screening (HTS) with phospho-NTRK1 antibodies presents unique challenges but offers valuable opportunities for drug discovery and pathway analysis:

• Assay Development Considerations:

• Platform-Specific Recommendations:

  • Cell-based assays: Use cell lines with stable NTRK1 expression; consider reporter systems

  • Protein microarrays: Maintain phosphorylation during printing and processing

  • High-content imaging: Include subcellular localization analysis

  • Automated western blotting: Standardize sample preparation to minimize variability

• Quality Control Measures:

  • Include on-plate phosphorylation standards

  • Implement plate normalization procedures

  • Use technical replicates across different plate positions

  • Include compounds with known effects as internal controls

• Data Analysis Approaches:

  • Normalize to total NTRK1 when possible

  • Consider machine learning for pattern recognition

  • Perform clustering analysis to identify compound classes

  • Validate hits with orthogonal assays

Research has successfully used phosphorylation status screening to identify compounds that can overcome resistance to NTRK inhibitors. This approach led to the discovery that ponatinib and nintedanib effectively inhibit some resistant NTRK1 mutants, while cabozantinib combined with IGF1R inhibitors can address bypass pathway-mediated resistance .